Sales Representative - Physician Office
About the job
- A bachelor's degree and at least 2 years of quota-based sales experience, or at least 5 years of quota-based sales experience, with a background in cold calling, commissioned sales, and full-cycle sales.
- A demonstrable track record of sales growth and quota attainment.
- The ability to present multiple product lines.
- Computer proficiency, especially in Microsoft Excel, Word, and Outlook.
- The ability to drive a car, travel in that car for 90% of each day, and interact with healthcare providers on site.
- Grow and develop a territory of medical supplies, including disposables, exam gloves, point-of-care tests, capital equipment, and diagnostics.
- Build relationships and develop a customer base of alternate-site physician offices and hospital-based practices.
- Make new calls daily to develop new customers.
- Work with manufacturers to present products to the physician community.
- Prepare and deliver product quotations.
- Develop long-term relationships with the customer base.
- Prepare and maintain a territory plan.
- Create and grow a residual customer base in the alternate-site marketplace.
- Train on and learn new items to present to customers and explain their medical and fiscal benefits.
- Excellent communication and organizational skills.
- Stable work history.
About the company
Medline makes and distributes medical and surgical supplies for hospitals, surgery centers, nursing homes, physician offices and other care sites. It runs its own factories alongside a large network of warehouses and delivery routes, so one company can produce exam gloves, gowns and surgical kits and then deliver them straight to the bedside. Many health systems sign multi-year prime vendor agreements that make Medline the source for most of their medical-surgical supplies. It earns money selling its own products and those of other manufacturers, together with supply chain services. Medline was founded in 1966 and is based in Northfield, Illinois.
Company Size
10,001+
Company Stage
IPO
Headquarters
Northfield, Illinois
Founded
1966
Get referred to Medline
See people who can refer or advise you
Simplify's Take
What believers are saying
- Sales keep climbing: net sales rose 11.6% to $7.7 billion in the April to June 2026 quarter.
- Medline pays for school: full-time staff get 80% of tuition reimbursed, starting 30 days after hire for undergraduate study.
- A deep network absorbs shocks: losing its Tracy, California warehouse in June 2026 cut only about 4% of US space.
What critics are saying
- Quality lapses hit stock grants: shares fell 7% after a May 2026 FDA warning over contamination at a Medline plant.
- Tariffs squeeze profit: second-quarter 2026 net income fell 58% to $139 million as tariffs raised product costs.
- Buyout firms still hold sway: Blackstone, Carlyle and Hellman & Friedman each kept about 18% of Medline after listing.
What makes Medline unique
- Medline sells mostly its own goods: its Medline Brand products made 47.1% of net sales in early 2026.
- Medline drives its own deliveries: a fleet of over 2,100 MedTrans trucks reaches 95% of its US operations next day.
- The founding family keeps a voice: the Mills family held 17.8% of voting power after Medline listed.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Paid Vacation
Paid Sick Leave
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Medline launches enhanced TrackPoint(TM) to simplify inventory management for post-acute care. Oct 12, 2026, 16:25 ET Combines real-time inventory tracking with PointClickCare(R) integration to reduce manual work and improve supply visibility NORTHFIELD, Ill., Oct. 12, 2026 /PRNewswire/ - Medline (Nasdaq: MDLN) today announced the launch of an enhanced version of TrackPoint(TM), its online inventory management and patient item usage solution designed to help long-term care and inpatient hospice providers more easily track supplies from Medline, capture patient-level usage and gain visibility into inventory across locations. TrackPoint provides an easy-to-use solution that helps facilities streamline how they order and manage supplies purchased from Medline. The platform gives providers greater control over supply management by automating manual workflows and enabling more accurate tracking of what is on hand, where products are used and when replenishment is needed. "We know that our customers, especially in post-acute care, often don't have access to inventory management solutions and charge-capturing systems purpose-built for them," said Dave Kordik, vice president customer technology solutions, Medline. "Everything is very manual. We saw an opportunity to provide a more streamlined, modernized application for them." TrackPoint integrates with PointClickCare(R) for real-time patient data synching and helps providers improve inventory efficiency through several core capabilities: * Real-time Medline inventory visibility to understand what is on hand, where it is located, and what needs to be restocked. * Patient item and service usage tracking to support more accurate documentation and data needed for proactive care and operational efficiency. * Standardized workflows to create consistent processes for receiving, dispensing and tracking supplies and services. * Reduced manual work and errors through digital processes and barcode scanning. * Simplified purchasing through Medline.com to streamline ordering and reduce duplicate data entry. * Accurate multi-location inventory to manage multiple facilities for better counts and replenishment to align supply spend with patient needs and services delivered. "Our goal is to make inventory management easier and more actionable for long-term care and inpatient hospice providers," said Renee Fisher, senior vice president, national field sales, post-acute care, Medline. "We're excited to help customers improve visibility into supply usage, streamline everyday workflows and make more informed decisions that support both operational efficiency and patient care." About Medline Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com. SOURCE Medline
UNIQURE N.V. QURE INVESTORS: contact Kirby McInerney LLP about the firm's securities investigation following 37.3% share drop. NEW YORK-(BUSINESS WIRE)-The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. What Happened? On September 29, 2026, uniQure released 48-month data for ongoing Phase I/II studies of AMT-130, the Company's lead pipeline candidate to treat Huntington's disease. The 48-month data revealed a smaller treatment benefit than the one the Company reported at 36 months. Specifically, AMT-130 showed a "44% slowing of disease progression" at 48 months under the composite Uniform Huntington's Disease Rating Scale, compared to a 75% disease slowing at 36 months. In June, uniQure had announced that the Company intended to submit an application to the FDA to bring AMT-130 to the market and did so on September 2, 2026, submitting a Biologics License Application to the FDA based upon its 36-month data analysis. On the disclosure of the Company's 48-month AMT-130 results, the price of uniQure shares declined by $14.60 per share, or approximately 37.3%, from $39.11 per share on September 28, 2026 to close at $24.51 on September 29, 2026. What Should I Do? At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. If you purchased or otherwise acquired uniQure securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP's website. More News From Kirby McInerney LLP NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM'S INVESTIGATION]What Happened?On June 2, 2026, the FDA published a warning letter that detailed Medline's "significant violations of Curr... NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Alphabet Inc. ("Alphabet" or the "Company") (NASDAQ: GOOGL; GOOG) securities between May 19, 2026 and July 16, 2026, inclusive ("the Class Period"). If you suffered a loss on your Alphabet investments, you have until December 1, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Investors are encouraged to fill ou... NEW YORK-( BUSINESS WIRE )-The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Coastal Financial Corporation ("Coastal" or the "Company") (NASDAQ: CCB) securities between October 28, 2024 and July 29, 2026, inclusive ("the Class Period"). If you suffered a loss on your Coastal investments, you have until December 1, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Investors are encouraged... Kirby McInerney LLP. NASDAQ:QURE Release Versions
Bragar Eagel & Squire, P.C. is investigating Medline Inc. on behalf of Medline stockholders and Encourages Investors to contact the firm. Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medline (MDLN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Medline and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648. NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) - What's Happening: * Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN) on behalf of Medline stockholders. Our investigation concerns whether Medline has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details: * On June 2, 2026, the FDA published a warning letter that detailed Medline's "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals," including failing "to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." On this news, the price of Medline shares declined by $2.56 per share, or approximately 7.2%, from $35.75 per share on to June 1, 2026 to close at $33.19 on June 2, 2026. * On August 5, 2026, Medline released its second quarter 2026 financial results and revealed during its earnings call that some of the remediation steps it has taken in response to the FDA's letter, such as taking products off the market, have "result[ed] in earnings loss." On this news, the price of Medline shares declined by $5.37 per share, or approximately 12.8%, from $42.04 per share on August 4, 2026 to close at $36.67 on August 5, 2026. Next Steps: * If you purchased or otherwise acquired Medline shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 [email protected] www.bespc.com
James River Home Health selects Medline vendor. Medline announced it signed a new Prime Vendor agreement with James River Home Health & Hospice, a home health and hospice provider serving patients and families across its care network, a James River Home Health Medline Prime Vendor arrangement aimed at supporting the provider's growth. What the James River Home Health Medline Prime Vendor agreement includes. Through the agreement, James River gains access to Medline's medical-surgical product portfolio and distribution capabilities, intended to streamline ordering and timely, reliable delivery of supplies. The Prime Vendor model typically consolidates a provider's purchasing with one distributor, which can simplify logistics and standardize the products clinicians use. Clinical tools added to the arrangement. James River will also implement Medline's Skin Health Program and use the NE1 Wound Tool, which helps clinical staff assess and document wounds. Pairing supply purchasing with clinical programs suggests the agreement is meant to support care consistency as well as procurement. James River's rationale for the James River Home Health Medline Prime Vendor deal. David Gilligan, CFO of James River Home Health & Hospice, described the organization as a growing provider focused on expanding access to high-quality care. He said building infrastructure and partnerships to support clinicians and maintain consistency is a priority, and that Medline's scale, expertise, and post-acute focus make it a strong partner as James River serves more patients. Why consistency matters as providers grow. Expanding home-based providers often add clinicians and locations quickly, which can produce variation in the supplies and documentation practices staff use. Standardizing on a single vendor and shared tools is one way to keep practices uniform across a growing network. Medline's perspective on the James River Home Health Medline Prime Vendor agreement. Renee Fisher, senior vice president of national field sales for post-acute care at Medline, said the company is proud to work with James River as it expands access to home-based care. She said the combination of reliable product access and post-acute supply chain solutions is meant to let James River's teams stay focused on patients and families. About Medline. Medline describes itself as the largest provider of medical-surgical products and supply chain solutions serving all points of care, employing more than 45,000 people worldwide and operating in more than 100 countries. The company trades on Nasdaq under MDLN and is headquartered in Northfield, Ill. How the James River Home Health Medline Prime Vendor agreement fits home-based care trends. The announcement reflects a theme raised at recent home-based care events, where operators said growth must rest on operational infrastructure and discipline. Supply chain reliability, clinical documentation, and compliance are part of that backbone, particularly as federal fraud enforcement and documentation scrutiny continue to affect home health and hospice providers. Why Wound documentation is a notable detail. Wound assessment and documentation are areas where consistent records matter for both clinical care and payer or regulatory review. Providing a standard tool for staff may help James River document care uniformly, though the announcement did not describe outcomes or metrics. What the James River Home Health Medline Prime Vendor agreement means going forward. The agreement gives James River a single supply and clinical program partner as it grows, and it gives Medline another post-acute customer. Because financial terms, contract length, and the size of James River's network were not disclosed, the practical impact on costs and operations cannot be assessed from the announcement alone. What to watch going forward. Observers will likely watch whether James River reports operational or clinical results from the Skin Health Program and NE1 Wound Tool, and whether more home health and hospice providers pursue similar prime vendor and clinical program bundles. As a company announcement, the James River Home Health Medline Prime Vendor news is best read as a signal of provider growth and vendor consolidation in post-acute care rather than as evidence of measured performance gains.
MDLN Stock Drop alert: Medline Stock plummets 13% after product quality issues revealed - BFA Law notifies investors of its ongoing Securities Fraud investigation. BFA Law is investigating whether Medline Inc. committed securities fraud relating to statements about Medline's manufacturing and product quality. NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit. Key Details of the Medline ($MDLN) Class Action Investigation: * Investigation Overview: Securities fraud relating to Medline's statements about its manufacturing and product quality. * Stock Declines: June 2, 2026 - 7% Stock Drop August 5, 2026 - 13% Stock Drop * Action: Contact BFA Law to discuss your rights Why is Medline Being Investigated for Securities Fraud? Medline is a healthcare manufacturing and supply-chain company that retails and distributes medical and surgical products. BFA is investigating whether Medline misled investors about its manufacturing and product quality. Why did Medline's Stock Drop? On June 2, 2026, the FDA published a warning letter detailing Medline's "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals" and stating that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." Following that announcement, Medline shares fell approximately 7% on June 2, 2026. Then, before market hours on August 5, 2026, Medline acknowledged that at least some of remediation steps taken to address the issues in the FDA's warning letter had "result[ed] in earnings loss" during the company's 2Q26 earnings call. Following that announcement, Medline shares fell approximately 13% on August 5, 2026. What Can You Do? If you invested in Medline securities, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes.